Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm Licenses Protein Crystallization Technology from Syrrx

NEW YORK, Feb. 3 (GenomeWeb News) - Microfluidics developer Fluidigm has obtained non-exclusive license rights to Syrrx's submicroliter protein crystallization technology, the companies said today.

The terms of the licensing agreement were not disclosed.

Syrrx said it obtained "broad patent protection" for the crystallization of proteins in submicroliter volumes through an exclusive license with Lawrence Berkeley National Laboratory. Fluidigm's non-exclusive license will provide it with freedom to operate relative to Syrrx's patent portfolio, the companies said.

Fluidigm said it acquired the license to support the commercialization of its Topaz protein crystallization platform, which relies on chips that consume only nanogram quantities of protein per trial.

David Weitz, Syrrx's general counsel, said in a statement that Fluidigm is the first system manufacturer to license the company's technology, and that Syrrx "looks forward to securing other licensees as submicroliter crystallization is more widely adopted."